EU/3/11/850: Orphan designation for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Darinaparsin
Table of contents
Overview
On 15 April 2011, orphan designation (EU/3/11/850) was granted by the European Commission to Ziopharm Oncology Limited, United Kingdom, for darinaparsin for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).
Key facts
Active substance |
Darinaparsin
|
Intended use |
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/11/850
|
Date of designation |
15/04/2011
|
Sponsor |
IDEA Innovative Drug European Associates (Ireland) Limited Unit 13 Classon House E-mail: inquires@krystalbio.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
July 2022 | The sponsor’s address was updated in July 2022. |
February 2019 | The sponsorship was transferred to IDEA Innovative Drug European Associates (Ireland) Limited, Republic of Ireland, in February 2019. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: